Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

Core Insights - Bioxytran, Inc. announced positive clinical results from its Phase 2 trial of ProLectin-M, showing complete elimination of viral load in 100% of patients by day 7 compared to placebo (p=.001) [1][8] Study Design and Results - The Phase 2 clinical study was a randomized, double-blind, placebo-controlled trial involving 38 subjects, all of whom completed the study [3] - Subjects received one of three ProLectin-M dose levels or a matching placebo over a seven-day treatment period [3] - Viral shedding was assessed using RT-PCR analysis of nasopharyngeal swabs, with viral clearance defined as non-detection of viral RNA below established PCR thresholds [4] Viral Clearance Outcomes - The study confirmed earlier findings of significant reductions in viral load by Day 7, with early clearance observed as soon as Day 3 and no viral rebounds during a 14-day post-treatment observation period [5] - By Day 3, 1 of 38 subjects showed non-detection of viral shedding; by Day 5, 16 of 38; and by Day 7, all 38 subjects demonstrated non-detection [8] Mechanism of Action - ProLectin-M is distinguished by its novel mechanism of action, targeting viral entry at the cell surface rather than viral replication inside the cell, potentially reducing reliance on immune activation [9] Future Plans - Based on the trial results, Bioxytran plans to advance regulatory discussions for late-stage clinical development and evaluate ProLectin-M for additional viral indications [10] Company Overview - Bioxytran, Inc. is a clinical-stage biotechnology company focused on developing carbohydrate-based therapeutics to address unmet medical needs in virology and other disease areas [11]